TY - JOUR
T1 - Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation
AU - Mylonas, Chrystalleni
AU - Zwas, Shifra T.
AU - Rotenberg, Galina
AU - Omry, Gal
AU - Cohen, Ohad
PY - 2014/2
Y1 - 2014/2
N2 - Background: To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. objectives: To demonstrate the efficacy of rhTSH in radio-iodine thyroid ablation in patients with differentiated thyroid cancer. methods: We conducted a retrospective study of patients who underwent total thyroidectomy for well-differentiated thyroid cancer with different levels of risk, treated with rhTSH prior to remnant ablation with radioiodine. results: Seventeen patients with thyroid cancer were studied and followed for a median of 25 months (range 8-49 months). Ablation (defined as stimulated thyroglobulin < 1 mg/ml and negative neck ultrasonography) was successful in 15 patients (88.2%). One of the patients was lost to follow-up. conclusions: The use of rhTSH with postoperative radioiodine ablation may be an efficient tool for sufficient thyroid remnant ablation, avoiding hypothyroidal state in the management of thyroid cancer patients.
AB - Background: To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. objectives: To demonstrate the efficacy of rhTSH in radio-iodine thyroid ablation in patients with differentiated thyroid cancer. methods: We conducted a retrospective study of patients who underwent total thyroidectomy for well-differentiated thyroid cancer with different levels of risk, treated with rhTSH prior to remnant ablation with radioiodine. results: Seventeen patients with thyroid cancer were studied and followed for a median of 25 months (range 8-49 months). Ablation (defined as stimulated thyroglobulin < 1 mg/ml and negative neck ultrasonography) was successful in 15 patients (88.2%). One of the patients was lost to follow-up. conclusions: The use of rhTSH with postoperative radioiodine ablation may be an efficient tool for sufficient thyroid remnant ablation, avoiding hypothyroidal state in the management of thyroid cancer patients.
KW - Recombinant human thyroid-stimulating hormone (rhTSH)
KW - Thyroid cancer
KW - Thyroid remnant ablation
UR - http://www.scopus.com/inward/record.url?scp=84893864204&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84893864204
SN - 1565-1088
VL - 16
SP - 106
EP - 109
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 2
ER -